NASDAQ:SLNO Soleno Therapeutics (SLNO) Stock Forecast, Price & News $29.51 +1.92 (+6.96%) (As of 09/29/2023 08:53 PM ET) Add Compare Share Share Today's Range$24.25▼$30.2950-Day Range$3.74▼$29.5152-Week Range$0.85▼$30.30Volume3.02 million shsAverage Volume415,468 shsMarket Capitalization$294.80 millionP/E RatioN/ADividend YieldN/APrice Target$37.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Soleno Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside25.4% Upside$37.00 Price TargetShort InterestHealthy2.48% of Float Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.65Based on 33 Articles This WeekInsider TradingAcquiring Shares$15.12 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.34) to ($1.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.59 out of 5 starsMedical Sector128th out of 970 stocksElectromedical Equipment Industry3rd out of 20 stocks 3.5 Analyst's Opinion Consensus RatingSoleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.00, Soleno Therapeutics has a forecasted upside of 25.4% from its current price of $29.51.Amount of Analyst CoverageSoleno Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.48% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 151.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSoleno Therapeutics does not currently pay a dividend.Dividend GrowthSoleno Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSoleno Therapeutics has received a 73.45% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for genetic diseases" and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Soleno Therapeutics is -0.55. Previous Next 3.1 News and Social Media Coverage News SentimentSoleno Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for Soleno Therapeutics this week, compared to 1 article on an average week.Search Interest28 people have searched for SLNO on MarketBeat in the last 30 days. This is an increase of 2,700% compared to the previous 30 days.MarketBeat Follows3 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Soleno Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,115,340.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders23.70% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Soleno Therapeutics are expected to grow in the coming year, from ($2.34) to ($1.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soleno Therapeutics is -9.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soleno Therapeutics is -9.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoleno Therapeutics has a P/B Ratio of 23.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Soleno Therapeutics (NASDAQ:SLNO) StockSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Read More SLNO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLNO Stock News HeadlinesOctober 2, 2023 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) to Post FY2024 Earnings of ($1.52) Per Share, Cantor Fitzgerald ForecastsOctober 1, 2023 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Major Shareholder Perceptive Advisors Llc Acquires 250,000 SharesOctober 2, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.October 1, 2023 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Major Shareholder Perceptive Advisors Llc Purchases 616,789 SharesSeptember 29, 2023 | msn.comSoleno Therapeutics' 10% owner buys $15M worth of stockSeptember 27, 2023 | finance.yahoo.comSoleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded WarrantsSeptember 27, 2023 | finance.yahoo.comWhy Shares of Soleno Therapeutics Dropped on WednesdaySeptember 27, 2023 | finance.yahoo.comSoleno Therapeutics Stock Dives After Its Meteoric Rise on Positive Study ResultsOctober 2, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 27, 2023 | finance.yahoo.comIndividual investors in Soleno Therapeutics, Inc. (NASDAQ:SLNO) are its biggest bettors, and their bets paid off as stock gained 494% last weekSeptember 27, 2023 | finance.yahoo.comSoleno (SLNO) Soars as Prader-Willi Syndrome Study Meets GoalSeptember 27, 2023 | americanbankingnews.comOppenheimer Raises Soleno Therapeutics (NASDAQ:SLNO) Price Target to $39.00September 27, 2023 | americanbankingnews.comSoleno Therapeutics (NASDAQ:SLNO) Price Target Increased to $35.00 by Analysts at Cantor FitzgeraldSeptember 26, 2023 | marketwatch.comSoleno Therapeutics Shares Take Flight After Strong Study DataSeptember 26, 2023 | markets.businessinsider.comSoleno Therapeutics' Study Outcome Bolsters Confidence In PWS TreatmentSeptember 26, 2023 | finance.yahoo.comSoleno Catapults 505% After Its Pill Controls Hunger In Obesity-Causing Genetic DiseaseSeptember 26, 2023 | markets.businessinsider.comSoleno Says Study C602 Met Primary Endpoint; Stock Surges In PremarketSeptember 26, 2023 | msn.comGenetic Disorder Focused Soleno Therapeutics' Stock Is Trading 4X Today - Here's Why?September 26, 2023 | finance.yahoo.comSoleno Catapults Almost 400% After Its Pill Controls Hunger In Obesity-Causing Genetic DiseaseSeptember 26, 2023 | finance.yahoo.comWhy Shares of Soleno Therapeutics Are Booming on TuesdaySeptember 26, 2023 | investorplace.comWhy Is Soleno Therapeutics (SLNO) Stock Up 420% Today?September 26, 2023 | marketwatch.comSoleno Therapeutics Shares Soar Premarket on Prader-Willi Study SuccessSeptember 26, 2023 | finance.yahoo.comSoleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi SyndromeSeptember 25, 2023 | finance.yahoo.comSoleno Therapeutics to Present at the Cantor Global Healthcare ConferenceSeptember 23, 2023 | americanbankingnews.comSoleno Therapeutics (NASDAQ:SLNO) Share Price Passes Below 200-Day Moving Average of $4.18September 15, 2023 | msn.comOppenheimer Maintains Soleno Therapeutics (SLNO) Outperform RecommendationSeptember 15, 2023 | markets.businessinsider.comOppenheimer Maintains Outperform Rating for Soleno Therapeutics: Here's What You Need To KnowSee More Headlines Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLNO Company Calendar Last Earnings8/08/2023Today10/02/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLNO CUSIPN/A CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees25Year FoundedN/APrice Target and Rating Average Stock Price Forecast$37.00 High Stock Price Forecast$39.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+25.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-280.20% Return on Assets-104.44% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio2.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book23.24Miscellaneous Outstanding Shares9,990,000Free Float7,624,000Market Cap$294.80 million OptionableNot Optionable Beta0.15 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Anish Bhatnagar M.D. (Age 53)Pres, CEO, COO & Director Comp: $835.2kMr. James H. MacKaness (Age 59)Chief Financial Officer Comp: $539kMs. Patricia C. Hirano (Age 57)VP of Regulatory Affairs Comp: $423.8kDr. Neil M. Cowen M.B.A.Ph.D., MBA, Sr. VP of Drug Devel.Ms. Kristen Yen M.S. (Age 54)VP of Clinical Operations Key CompetitorsZynexNASDAQ:ZYXIEdap TmsNASDAQ:EDAPAxoGenNASDAQ:AXGNSemler ScientificNASDAQ:SMLRPixie Dust TechnologiesNASDAQ:PXDTView All CompetitorsInsiders & InstitutionsPerceptive Advisors LlcBought 250,000 shares on 9/28/2023Total: $5 M ($20.00/share)Perceptive Advisors LlcBought 616,789 shares on 9/26/2023Total: $10.12 M ($16.40/share)Perceptive Advisors LLCBought 2,207,753 shares on 8/24/2023Ownership: 22.100%Worth Venture Partners LLCSold 13,055 shares on 8/15/2023Ownership: 0.909%Renaissance Technologies LLCSold 10,461 shares on 8/11/2023Ownership: 0.661%View All Insider TransactionsView All Institutional Transactions SLNO Stock - Frequently Asked Questions Should I buy or sell Soleno Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLNO shares. View SLNO analyst ratings or view top-rated stocks. What is Soleno Therapeutics' stock price forecast for 2023? 2 equities research analysts have issued 1-year price targets for Soleno Therapeutics' stock. Their SLNO share price forecasts range from $35.00 to $39.00. On average, they anticipate the company's stock price to reach $37.00 in the next year. This suggests a possible upside of 25.4% from the stock's current price. View analysts price targets for SLNO or view top-rated stocks among Wall Street analysts. How have SLNO shares performed in 2023? Soleno Therapeutics' stock was trading at $1.98 at the beginning of 2023. Since then, SLNO stock has increased by 1,390.4% and is now trading at $29.51. View the best growth stocks for 2023 here. Are investors shorting Soleno Therapeutics? Soleno Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 200,500 shares, an increase of 151.9% from the August 31st total of 79,600 shares. Based on an average daily volume of 699,300 shares, the days-to-cover ratio is currently 0.3 days. Approximately 2.5% of the company's stock are sold short. View Soleno Therapeutics' Short Interest. When is Soleno Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our SLNO earnings forecast. How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.11. When did Soleno Therapeutics' stock split? Shares of Soleno Therapeutics reverse split before market open on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD). What is Soleno Therapeutics' stock symbol? Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO." How do I buy shares of Soleno Therapeutics? Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Soleno Therapeutics' stock price today? One share of SLNO stock can currently be purchased for approximately $29.51. How much money does Soleno Therapeutics make? Soleno Therapeutics (NASDAQ:SLNO) has a market capitalization of $294.80 million. The company earns $-24,070,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis. How can I contact Soleno Therapeutics? Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The official website for the company is www.soleno.life. The company can be reached via phone at (650) 213-8444, via email at ir@soleno.life, or via fax at 650-213-8383. This page (NASDAQ:SLNO) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.